Human Monoclonal Antibodies to Influenza Virus: IgG Subclass and Light Chain Distribution

1989 ◽  
Vol 2 (1) ◽  
pp. 31-36 ◽  
Author(s):  
ARTHUR L. FRANK ◽  
HOWARD R. SIX ◽  
ALEJANDRO MARCHINI
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Light Chain ◽  
Igg Subclass ◽  
Human Monoclonal Antibodies ◽  
Light Chain Distribution

scholarly journals Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Nature ◽  
2008 ◽  
Vol 453 (7195) ◽  
pp. 667-671 ◽  
Author(s):  
Jens Wrammert ◽  
Kenneth Smith ◽  
Joe Miller ◽  
William A. Langley ◽  
Kenneth Kokko ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Human Monoclonal Antibodies ◽  
High Affinity

scholarly journals Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors

2009 ◽  
Vol 387 (1) ◽  
pp. 180-185 ◽  
Author(s):  
Ritsuko Kubota-Koketsu ◽  
Hiroyuki Mizuta ◽  
Masatoshi Oshita ◽  
Shoji Ideno ◽  
Mikihiro Yunoki ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Human Monoclonal Antibodies ◽  
Healthy Donors

Molecular Characterization of Variable Heavy and Light Chain Regions of Five HIV Type 1-Specific Human Monoclonal Antibodies*

1994 ◽  
Vol 10 (12) ◽  
pp. 1639-1649 ◽  
Author(s):  
ERIC M.M. van der DONK ◽  
MARTIN SCHUTTEN ◽  
ALBERT D.M.E. OSTERHAUS ◽  
ROGER W.J. van der HEIJDEN
Keyword(s):  
Monoclonal Antibodies ◽  
Molecular Characterization ◽  
Light Chain ◽  
Human Monoclonal Antibodies ◽  
Variable Heavy ◽  
Hiv Type 1

scholarly journals Influenza virus glycoprotein-reactive human monoclonal antibodies

2020 ◽  
Vol 22 (6-7) ◽  
pp. 263-271
Author(s):  
Yanbai Li ◽  
Lili Wang ◽  
Helong Si ◽  
Zhengsen Yu ◽  
Shijun Tian ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Human Monoclonal Antibodies ◽  
Virus Glycoprotein

scholarly journals Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge

2018 ◽  
Vol 92 (16) ◽  
Author(s):  
Raffael Nachbagauer ◽  
David Shore ◽  
Hua Yang ◽  
Scott K. Johnson ◽  
Jon D. Gabbard ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Influenza Viruses ◽  
Health Concern ◽  
Human Monoclonal Antibodies ◽  
Lethal Challenge ◽  
Highly Pathogenic ◽  
Zoonotic Infections ◽  
Stalk Domain ◽  
Group 1

ABSTRACT Broadly cross-reactive antibodies (Abs) that recognize conserved epitopes within the influenza virus hemagglutinin (HA) stalk domain are of particular interest for their potential use as therapeutic and prophylactic agents against multiple influenza virus subtypes, including zoonotic virus strains. Here, we characterized four human HA stalk-reactive monoclonal antibodies (MAbs) for their binding breadth and affinity, in vitro neutralization capacity, and in vivo protective potential against an highly pathogenic avian influenza virus. The monoclonal antibodies were isolated from individuals shortly following infection with (70-1F02 and 1009-3B05) or vaccination against (05-2G02 and 09-3A01) A(H1N1)pdm09. Three of the MAbs bound HAs from multiple strains of group 1 viruses, and one MAb, 05-2G02, bound to both group 1 and group 2 influenza A virus HAs. All four antibodies prophylactically protected mice against a lethal challenge with the highly pathogenic A/Vietnam/1203/04 (H5N1) strain. Two MAbs, 70-1F02 and 09-3A01, were further tested for their therapeutic efficacy against the same strain and showed good efficacy in this setting as well. One MAb, 70-1F02, cocrystallized with H5 HA and showed heavy-chain-only interactions similar to those seen with the previously described CR6261 anti-stalk antibody. Finally, we show that antibodies that compete with these MAbs are prevalent in serum from an individual recently infected with the A(H1N1)pdm09 virus. The antibodies described here can be developed into broad-spectrum antiviral therapeutics that could be used to combat infections by zoonotic or emerging pandemic influenza viruses. IMPORTANCE The rise in zoonotic infections of humans by emerging influenza viruses is a worldwide public health concern. The majority of recent zoonotic human influenza cases were caused by H7N9 and H5Nx viruses and were associated with high morbidity and mortality. In addition, seasonal influenza viruses are estimated to cause up to 650,000 deaths annually worldwide. Currently available antiviral treatment options include only neuraminidase inhibitors, but some influenza viruses are naturally resistant to these drugs, and others quickly develop resistance-conferring mutations. Alternative therapeutics are urgently needed. Broadly protective antibodies that target the conserved “stalk” domain of the hemagglutinin represent potential potent antiviral prophylactic and therapeutic agents that can assist pandemic preparedness. Here, we describe four human monoclonal antibodies that target conserved regions of influenza HA and characterize their binding spectrum as well as their protective capacity in prophylactic and therapeutic settings against a lethal challenge with a zoonotic influenza virus.

Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1994 ◽  
Vol 7 (1) ◽  
pp. 13-21 ◽  
Author(s):  
L.L. Green ◽  
M.C. Hardy ◽  
C.E. Maynard-Currie ◽  
H. Tsuda ◽  
D.M. Louie ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Light Chain ◽  
Human Monoclonal Antibodies

scholarly journals Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase

2021 ◽  
Author(s):  
Ericka Kirkpatrick Roubidoux ◽  
Meagan McMahon ◽  
Juan Manuel Carreno ◽  
Christina Capuano ◽  
Kaijun Jiang ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Serial Passage ◽  
Viral Fitness ◽  
Escape Mutant ◽  
Human Antibody ◽  
Human Monoclonal Antibodies ◽  
Influenza Virus Neuraminidase

Influenza virus neuraminidase (NA) targeting antibodies are an independent correlate of protection against infection. Antibodies against the NA act by blocking enzymatic activity, preventing virus release and transmission. As we advance the development of improved influenza virus vaccines that incorporate standard amounts of NA antigen, it is important to identify the antigenic targets of human monoclonal antibodies (mAbs). Additionally, it is important to understand how escape from mAbs changes viral fitness. Here, we describe escape mutants generated by serial passage of A/Netherlands/602/2009 (H1N1) in the presence of human anti-N1 mAbs. We observed escape mutations on the N1 protein around the enzymatic site (S364N, N369T and R430Q) and also detected escape mutations located on the sides and bottom of the NA (N88D, N270D and Q313K/R). We found that a majority of escape mutant viruses had increased fitness in vitro but not in vivo. This work increases our understanding of how human antibody responses target the N1 protein.

Sign in / Sign up

Export Citation Format

Share Document